Compare Dover Corp (DOV) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Eli Lilly And Co — how do they compare? Dover Corp trades at $190.16 (market cap $25.45B), while Eli Lilly And Co trades at $1,169 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 40.9× Dover Corp's market cap, and Dover Corp pays the higher dividend (1.11%). Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and Eli Lilly And Co for 93 Days on average.
| DOV | LLY | |
|---|---|---|
Market Cap | $25.45B | $1.04T |
Volume | 661,758 | 3,064,878 |
Sector | Industrials | Health |
52-Week High | $233.31 | $1.28K |
52-Week Low | $161.16 | $799.57 |
Typical Hold Time | 73 Days | 93 Days |
Enterprise Value | $26.95B | $1.09T |
Dividend Yield | 1.11% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $188.29, down 1.87% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with a 13.48% net income margin and has beaten earnings expectations for three consecutive quarters. Recent acquisitions and product launches demonstrate ongoing business development. Analyst consensus remains strongly bullish with a $243.20 price target representing 29% upside potential.
The stock offers attractive upside based on analyst targets and consistent earnings performance, though technical indicators suggest near-term pressure. Key risks include market volatility and integration challenges from recent acquisitions. The company's Dividend King status and strong cash flow generation provide stability for long-term investors.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
